Sex difference in the antiplatelet effect of aspirin in patients with stroke

Annals of Pharmacotherapy

Volumn 40, Issue 5, 2006, Pages 812-817

  Cavallari, Larisa H ^a   Helgason, Cathy M ^b   Brace, Larry D ^b   Viana, Marlos A G ^b   Nutescu, Edith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Aspirin; Platelet aggregation; Sex; Stroke; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; BODY MASS; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; AGED; ASPIRIN; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SEX FACTORS;

EID: 33646777394     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G569     Document Type: Review

References (25)

1. 2005 Heart and stroke statistical update. Dallas: American Heart Association, 2004.
2. Hennerici MG. The unstable plaque. Cerebrovasc Dis 2004;17(suppl 3):17-22.
3. van Wijk I, Kappelle LJ, van Gijn J, et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005;365:2098-104.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
5. Forbes CD. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thromb Res 1998;92(1 suppl 1):S1-6.
6. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119(1 suppl):300S-20S.
7. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
8. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
9. Jovicic A, Ivanisevic V, Nikolajevic R. Circadian variations of platelet aggregability and fibrinolytic activity in patients with ischemic stroke. Thromb Res 1991;64:487-91.
10. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1964;194:927-9.
11. Fleiss J. The standardization of rates. In: Statistical methods for rates and proportions. 2nd ed. New York: John Wiley and Sons, 1981:237-55.
12. O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001;103:3051-6.
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
14. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
15. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6.
16. Nakayasu H, Maeda M, Soda T, et al. The antiplatelet aggregation effects of aspirin suppositories. Cerebrovasc Dis 2003;16:31-5.
17. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
18. Sivenius J, Laakso M, Penttila IM, Smets P, Lowenthal A, Riekkinen PJ. The European Stroke Prevention Study: results according to sex. Neurology 1991;41:1189-92.
19. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens 2000;18:629-42.
20. Bornstein NM, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD. Failure of aspirin treatment after stroke. Stroke 1994;25:275-7.
21. Chamorro A, Escolar G, Revilla M, et al. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. J Neurol Sci 1999;171:110-4.
22. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
23. 2 receptor density and aggregation responses. Circulation 1995;91:2742-7.
24. Spranger M, Aspey BS, Harrison MJ. Sex difference in antithrombotic effect of aspirin. Stroke 1989;20:34-7.
25. Williams MS, Vaidya D, Kickler T, Ouyang P. Long-term hormone replacement therapy does not cause increased platelet activation. Am Heart J 2005;150:434-8.